C L Scott

Summary

Affiliation: The Walter and Eliza Hall Institute of Medical Research
Country: Australia

Publications

  1. ncbi request reprint The beta common chain (beta c) of the granulocyte macrophage-colony stimulating factor, interleukin-3 and interleukin-5 receptors
    C L Scott
    Walter and Eliza Hall Institute of Medical Research, Parkvile, Vic, Australia
    Int J Biochem Cell Biol 31:1011-5. 1999
  2. ncbi request reprint Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor
    C L Scott
    The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Victoria, Australia
    Blood 96:1588-90. 2000
  3. ncbi request reprint Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice
    C L Scott
    The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia
    Exp Hematol 28:1001-7. 2000
  4. ncbi request reprint Thrombopoietin signaling is required for in vivo expansion of IL-11--responsive hematopoietic progenitor cells in the steady state
    C L Scott
    The Walter and Eliza Hall Institute of Medical Research, P O Royal Melbourne Hospital, Victoria, Australia
    Exp Hematol 29:138-45. 2001
  5. pmc Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
    L Happo
    Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Cell Death Dis 3:e306. 2012
  6. pmc Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis
    E M Michalak
    The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
    Cell Death Differ 16:684-96. 2009
  7. ncbi request reprint SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine
    W S Alexander
    The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia
    Cell 98:597-608. 1999
  8. pmc Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
    R K Lindemann
    Cancer Immunology Program, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 104:8071-6. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint The beta common chain (beta c) of the granulocyte macrophage-colony stimulating factor, interleukin-3 and interleukin-5 receptors
    C L Scott
    Walter and Eliza Hall Institute of Medical Research, Parkvile, Vic, Australia
    Int J Biochem Cell Biol 31:1011-5. 1999
    ..Intriguing observations suggesting altered susceptibility to some infectious agents and amelioration of responses to inflammatory stimuli, require further clarification...
  2. ncbi request reprint Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor
    C L Scott
    The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Victoria, Australia
    Blood 96:1588-90. 2000
    ..This study provided results that challenge conclusions previously established using a variety of biochemical assays. (Blood. 2000;96:1588-1590)..
  3. ncbi request reprint Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice
    C L Scott
    The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia
    Exp Hematol 28:1001-7. 2000
    ..To examine the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in thrombopoiesis...
  4. ncbi request reprint Thrombopoietin signaling is required for in vivo expansion of IL-11--responsive hematopoietic progenitor cells in the steady state
    C L Scott
    The Walter and Eliza Hall Institute of Medical Research, P O Royal Melbourne Hospital, Victoria, Australia
    Exp Hematol 29:138-45. 2001
    ..In this article, we identified a specific subset of bone marrow progenitor/stem cells that was altered in mpl(-/-) mice...
  5. pmc Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
    L Happo
    Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Cell Death Dis 3:e306. 2012
    ..These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours...
  6. pmc Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis
    E M Michalak
    The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
    Cell Death Differ 16:684-96. 2009
    ..They also indicate that additional BH3-only proteins probably also drive Myc-induced apoptosis and that non-apoptotic functions of p53 may contribute substantially to its tumour suppressor role...
  7. ncbi request reprint SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine
    W S Alexander
    The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia
    Cell 98:597-608. 1999
    ..Our data indicate that SOCS1 is a key modulator of IFNgamma action, allowing the protective effects of this cytokine to occur without the risk of associated pathological responses...
  8. pmc Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
    R K Lindemann
    Cancer Immunology Program, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 104:8071-6. 2007
    ..Our studies provide important information regarding the mechanisms of action of HDACi that have broad implications regarding stratification of patients receiving HDACi therapy alone or in combination with other anticancer agents...